Nano Letters · 2018 · 151 citations · 45 references
Life SciencesBiotechnologyPharmaceuticsDrug DeliveryNanobiotechnologyNanomaterialsCell-penetrating PeptidesDna NanotechnologyNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNucleic Acid DeliveryAntimicrobial NanomedicineAntisense RnasCell-penetrating Peptide NanocarriersDna NanocarriersDna NanomaterialsDrug Efflux MechanismsDrug-resistant PathogensNucleic Acid Nanotechnology
One of the biggest obstacles for the use of antisense oligonucleotides as antibacterial therapeutics is their limited uptake by bacterial cells without a suitable carrier, especially in multi-drug-resistant bacteria with a drug efflux mechanism. Existing vectors, such as cell-penetrating peptides, are inefficient and nontargeting, and accordingly are not ideal carriers. A noncytotoxic tetrahedral DNA nanostructure (TDN) with a controllable conformation has been developed as a delivery vehicle for antisense oligonucleotides. In this study, antisense peptide nucleic acids (asPNAs) targeting a specific gene ( ftsZ) were efficiently transported into methicillin-resistant Staphylococcus aureus cells by TDNs, and the expression of ftsZ was successfully inhibited in an asPNA-concentration-dependent manner. The delivery system specifically targeted the intended gene. This novel delivery system provides a better platform for future applications of antisense antibacterial therapeutics and provides a basis for the development of a new type of antibacterial drug for multi-drug-resistant bacterial infections.
45
DNA Origami as an <i>In Vivo</i> Drug Delivery Vehicle for Cancer Therapy
Qian Zhang, Qiao Jiang, Na Li et al. · ACS Nano · 2014 · 658 citations
Pharmacy, Oncology, Pharmaceutics +17
An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity
David J. Haydon, Neil R. Stokes, Rebecca Ure et al. · Science · 2008 · 443 citations · Full text